Insilico Medicine Chief Business Officer Michelle Chen has been named one of this year’s Top 25 Biotechnology Executives by the Healthcare Technology Report, a leading provider of healthcare sector news and research. eurekalert.org/news-releases/…

Insilico founder & CEO Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) is presenting at AIM Congress on May 9, a leading investment platform in the Middle East dedicated to igniting positive transformation through investment, about how #AI is driving new breakthroughs in #medicine . aimcongress.com

Big Pharma is betting on biotech. A story in The Economist looks at the #biotech revival - $5.1bn in investments in the first 3 months of 2024, 8 IPOs, 9 sales of $1bn+. Leading biotechs like Insilico offer pharma disease focus and #AI speed & innovation. economist.com/business/2024/…

Join Petrina Kamya, Head of AI Platforms, May 2 in Boston at the Amazon Web Services Life Sciences Leaders Symposium. She's part of a panel discussion on 'Moving Generative #AI From POCs to Enterprise Use.' The event showcases #genAI & #ML use cases in #pharma .
lnkd.in/eTSjqGKK

We're moving to #Boston ! Insilico is moving its global headquarters to 1000 Mass Ave. in #Cambridge where we will coordinate our global efforts and strategy and manage operations and business development as well as #sustainability and #AI policy. eurekalert.org/news-releases/…

Conformation - how #atoms are arranged in space - is key to molecular modeling. In a new paper, Insilico researchers revealed a new adversarial generative framework, COSMIC, that can provide insights into the 3D positioning and activity of #molecules . pubs.acs.org/doi/10.1021/ac…

Announcing FDA IND approval for Insilico's potentially best-in-class #AI -designed #MAT2A inhibitor, ISM3412.
MAT2A is a promising target for MTAP-deleted #cancers , found in 15% of all cancers. More in Genetic Engineering & Biotechnology News on the race to develop new treatments: genengnews.com/topics/artific…

At the recent World Future Energy Summit in the #UAE , Insilico Medicine founder & CEO Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) addressed how #AI & #biotech are contributing to the #sustainability of the human race and provided insights into the latest bio-inspired solutions for climate resilience. World Future Energy Summit

There's growing interest in WRN inhibitors - a promising synthetic lethality target for MMR deficient #cancer (colorectal, endometrial, ovarian). Insilico has 2 #AI -developed, novel, potent #WRN inhibitors, ISM9342A & ISM2196, w/ best-in-class potential. Email [email protected]

Are you at the sold out MassBio Align Summit?
Connect with Petrina Kamya, Ph.D. Global Head of AI Platforms at Insilico who is speaking at 12:30pm ET today on 'AI in Drug Discovery' w/ panelists from Eli Lilly and Company, Danaher Corporation, Microsoft, and Ginkgo Bioworks. massbio.org/events/listing…

#AI allows researchers to see the full potential of pipeline assets early in the process, to accelerate multiple new treatments for patients in need. Insilico is collaborating with invoX Pharma to ID new indications for pipeline assets in #oncology . eurekalert.org/news-releases/…

In a new Forbes column, Insilico founder & CEO Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) provides insights into the open-source strategy of #Llama3 & why Meta will be the 'dominant player in this game.' Yann LeCun argues that Llama will 'open the door to a large variety of players.' forbes.com/sites/alexzhav…

Connect w/ Insilico founder & CEO Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) at the World Economic Forum Special Meeting on Global Collaboration, Growth and Energy for Development in #Riyadh on April 28. The meeting will bring together over 700 leaders to discuss how to address #global challenges & drive #tech advances.

We're celebrating #EarthDay today and every day by advancing new solutions to pressing climate change problems using #genAI .

The Gazette, from the #French Association of Regulatory Affairs (AFAR), interviewed Insilico founder & CEO Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) on how Insilico is using #AI to improve the speed & efficiency of drug discovery, challenges to understanding AI decision-making & the role of regulations.

Petrina Kamya, Insilico's Global Head of AI Platforms, speaks on the panel 'Moving Generative AI From POCs to Enterprise Use' at the Amazon Web Services Life Sciences Leaders Symposium in Boston May 2nd, 3-3:30pm alongside panelists from Takeda🪁 & EPAM Systems. pages.awscloud.com/NAMER-event-T3…

Insilico's San Francisco team was thrilled to have a recent photo shoot with E24 - #Norway 's largest online newspaper for economics and business. Thank you Linn Kongsli Hillestad for featuring Insilico in your upcoming story on the latest advances in #AI drug discovery!

A new analysis from BiopharmaTrend compares the #novelty of #targets that #AI drug discovery companies are pursuing for their leading #drug programs, from low novelty to AI-discovered very novel targets like Insilico's TNIK for IPF. biopharmatrend.com/ai-drug-discov…

Congrats to Andrea Maier on a new study in Geroscience exploring the link between biological age & levels of inactivity in hospitalized older adults using SenoClock from DeepLongevity. Dr. Maier will be at the upcoming ARDD Meeting. link.springer.com/article/10.100… Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)

Insilico researchers used #genAI to discover a new class of Polθ inhibitors for #BRCA -deficient cancers. The molecules exhibited significant enzymatic and cellular potency and promising druglike properties, pointing to a novel strategy for targeting Polθ. eurekalert.org/news-releases/…